← Back to Clinical Trials
Recruiting NCT06062446

NCT06062446 A Prospective Study of a Modified Lumbar Puncture (LP) Procedure That Reduces Post-Lumbar Puncture Headaches (PLPH) in Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06062446
Status Recruiting
Phase
Sponsor The University of Texas Health Science Center, Houston
Condition Post-Lumbar Puncture Headache
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2023-11-08
Primary Completion 2026-04-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Modified Lumbar Puncture

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2023-11-08 with a primary completion date of 2026-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to o determine whether the modified LP procedure reduces the incidence of PLPH to 5% or lower, to determine whether the modified LP procedure reduces the frequency of epidural blood patch (EBP) usage to 10% or lower of the PLPH population and to identify factors that may contribute to or reduce incidence of PLPH

Eligibility Criteria

Inclusion Criteria: * Participants who can sign informed consent * Participants who have stated willingness to comply with all study procedures and availability for the duration of the study * Participants receiving a LP per standard of care (SOC) need for diagnostic or therapeutic purposes only * Participants with Karnofsky Performance Scale (KPS) ≥ 60 Exclusion Criteria: * Participants with a past medical history of chronic headaches (≥15 days per month) or acute headaches * Participants with recent neurosurgical device implants such as ventriculoperitoneal shunt * Participants with more than one dural puncture during the same LP procedure * Participants have chronic coagulopathy with elevated prothrombin time (PT), Partial thromboplastin time (PTT), and International Normalized ration (INR). * Participants who are on active anticoagulant or antiplatelet therapy unless stopped such therapy prior to LP per SOC guidance. * Participants with suspicions of raised intracranial pressure by either clinical assessment or imaging assessment or both * Participants with severe spinal column deformities, such as scoliosis. Disc diseases are not exclusion criteria * Participants with LP procedural complications that require a needle type or needle size change

Contact & Investigator

Central Contact

Jay-Jiguang Zhu, MD,PhD

✉ Jay.Jiguang.Zhu@uth.tmc.edu

📞 (713) 486-8000

Principal Investigator

Jay-Jiguang Zhu, MD,PhD

PRINCIPAL INVESTIGATOR

The University of Texas Health Science Center, Houston

Frequently Asked Questions

Who can join the NCT06062446 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Post-Lumbar Puncture Headache. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06062446 currently recruiting?

Yes, NCT06062446 is actively recruiting participants. Contact the research team at Jay.Jiguang.Zhu@uth.tmc.edu for enrollment information.

Where is the NCT06062446 trial being conducted?

This trial is being conducted at Houston, United States.

Who is sponsoring the NCT06062446 clinical trial?

NCT06062446 is sponsored by The University of Texas Health Science Center, Houston. The principal investigator is Jay-Jiguang Zhu, MD,PhD at The University of Texas Health Science Center, Houston. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology